CL2024003377A1 - Métodos para tratar la enfermedad de pompe - Google Patents
Métodos para tratar la enfermedad de pompeInfo
- Publication number
- CL2024003377A1 CL2024003377A1 CL2024003377A CL2024003377A CL2024003377A1 CL 2024003377 A1 CL2024003377 A1 CL 2024003377A1 CL 2024003377 A CL2024003377 A CL 2024003377A CL 2024003377 A CL2024003377 A CL 2024003377A CL 2024003377 A1 CL2024003377 A1 CL 2024003377A1
- Authority
- CL
- Chile
- Prior art keywords
- methods
- pompe disease
- treating pompe
- treating
- population
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/0102—Alpha-glucosidase (3.2.1.20)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263338601P | 2022-05-05 | 2022-05-05 | |
| US202263399498P | 2022-08-19 | 2022-08-19 | |
| US202263399491P | 2022-08-19 | 2022-08-19 | |
| US202263404475P | 2022-09-07 | 2022-09-07 | |
| US202263414897P | 2022-10-10 | 2022-10-10 | |
| US202263428970P | 2022-11-30 | 2022-11-30 | |
| US202263431920P | 2022-12-12 | 2022-12-12 | |
| US202263434791P | 2022-12-22 | 2022-12-22 | |
| US202363447222P | 2023-02-21 | 2023-02-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2024003377A1 true CL2024003377A1 (es) | 2025-03-28 |
Family
ID=86692686
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2024003377A CL2024003377A1 (es) | 2022-05-05 | 2024-11-05 | Métodos para tratar la enfermedad de pompe |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20260041744A1 (enExample) |
| EP (1) | EP4518885A1 (enExample) |
| JP (1) | JP2025515159A (enExample) |
| KR (1) | KR20250007602A (enExample) |
| CN (1) | CN119343147A (enExample) |
| AU (1) | AU2023265155A1 (enExample) |
| CA (1) | CA3252291A1 (enExample) |
| CL (1) | CL2024003377A1 (enExample) |
| CO (1) | CO2024016724A2 (enExample) |
| IL (1) | IL316776A (enExample) |
| MX (1) | MX2024013673A (enExample) |
| TW (1) | TW202400212A (enExample) |
| WO (1) | WO2023215865A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2026006625A1 (en) | 2024-06-26 | 2026-01-02 | Amicus Therapeutics, Inc. | Miglustat formulations comprising nitrosamine for use in the treatment of pompe disease |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6534300B1 (en) | 1999-09-14 | 2003-03-18 | Genzyme Glycobiology Research Institute, Inc. | Methods for producing highly phosphorylated lysosomal hydrolases |
| WO2009102895A2 (en) | 2008-02-12 | 2009-08-20 | Amicus Therapeutics, Inc. | Method to predict response to pharmacological chaperone treatment of diseases |
| US11382980B2 (en) | 2013-10-08 | 2022-07-12 | Taiyo Kagaku Co., Ltd. | Oil/fat composition containing polyunsaturated fatty acid |
| JP6851964B2 (ja) * | 2014-09-30 | 2021-03-31 | アミカス セラピューティックス インコーポレイテッド | 炭水化物が増大している非常に強力な酸性アルファ−グルコシダーゼ |
| IL299470B2 (en) * | 2015-12-30 | 2026-05-01 | Amicus Therapeutics Inc | Improved acid alpha-glucosidase for the treatment of Pompe disease |
| CA3019354A1 (en) | 2016-03-30 | 2017-10-05 | Amicus Therapeutics, Inc. | Method for selection of high m6p recombinant proteins |
| KR102618519B1 (ko) * | 2016-03-30 | 2023-12-28 | 아미쿠스 세라퓨틱스, 인코포레이티드 | 재조합 산 알파-글루코시다제를 포함하는 제형 |
| CN119113091A (zh) * | 2017-05-15 | 2024-12-13 | 阿米库斯治疗学公司 | 重组人类酸性α-葡萄糖苷酶 |
| WO2020163480A1 (en) | 2019-02-05 | 2020-08-13 | Amicus Therapeutics, Inc. | Recombinant human acid alpha-glucosidase and uses thereof |
| JP2024506346A (ja) * | 2021-02-11 | 2024-02-13 | アミカス セラピューティックス インコーポレイテッド | 組換えヒト酸性アルファグルコシダーゼ及びその使用 |
-
2023
- 2023-05-05 WO PCT/US2023/066657 patent/WO2023215865A1/en not_active Ceased
- 2023-05-05 KR KR1020247039256A patent/KR20250007602A/ko active Pending
- 2023-05-05 AU AU2023265155A patent/AU2023265155A1/en active Pending
- 2023-05-05 CA CA3252291A patent/CA3252291A1/en active Pending
- 2023-05-05 EP EP23728984.8A patent/EP4518885A1/en active Pending
- 2023-05-05 TW TW112116800A patent/TW202400212A/zh unknown
- 2023-05-05 JP JP2024565157A patent/JP2025515159A/ja active Pending
- 2023-05-05 CN CN202380045183.6A patent/CN119343147A/zh active Pending
- 2023-05-05 IL IL316776A patent/IL316776A/en unknown
- 2023-05-05 US US18/863,111 patent/US20260041744A1/en active Pending
-
2024
- 2024-11-05 MX MX2024013673A patent/MX2024013673A/es unknown
- 2024-11-05 CL CL2024003377A patent/CL2024003377A1/es unknown
- 2024-12-05 CO CONC2024/0016724A patent/CO2024016724A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2024013673A (es) | 2024-12-06 |
| IL316776A (en) | 2025-01-01 |
| CN119343147A (zh) | 2025-01-21 |
| CA3252291A1 (en) | 2023-11-09 |
| AU2023265155A1 (en) | 2024-12-12 |
| KR20250007602A (ko) | 2025-01-14 |
| WO2023215865A1 (en) | 2023-11-09 |
| US20260041744A1 (en) | 2026-02-12 |
| CO2024016724A2 (es) | 2025-04-28 |
| JP2025515159A (ja) | 2025-05-13 |
| EP4518885A1 (en) | 2025-03-12 |
| TW202400212A (zh) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112023016212A2 (pt) | Alfa-glucosidase ácida humana recombinante e usos da mesma | |
| BR112022011760A2 (pt) | Fragmento de alfa glicosidase ácida recombinante e/ou de alfa glicosidase ácida recombinante biologicamente ativa, alfa glicosidase ácida recombinante, composição, sequência polinucleotídica recombinante, vetor de expressão, vetor de expressão pdh, célula hospedeira, método para produzir uma variante de alfa glicosidase ácida recombinante, variante de alfa glicosidase ácida recombinante, composição farmacêutica para o tratamento da doença de pompe, composição farmacêutica, método para tratar e/ou prevenir os sintomas da doença de pompe em um indivíduo, e, uso das composições | |
| CO2024016724A2 (es) | Métodos para tratar la enfermedad de pompe | |
| CO2025008934A2 (es) | Fexamétodos para tratar la enfermedad de pompe de inicio infantil en pacientes pediátricos | |
| MX349992B (es) | Composiciones de alta concentracion de alfa-glucosidasa para el tratamiento de la enfermedad de pompe. | |
| CL2018002768A1 (es) | Formulaciones que comprenden alfa-glucosidasa ácida recombinante | |
| US20140187755A1 (en) | Clostridial neurotoxins with altered persistency | |
| BR112023001121A2 (pt) | Cepa c de prevotella histicola como uma terapia oral para doenças inflamatórias | |
| Jeong et al. | Sphingosine kinase 1 activation enhances epidermal innate immunity through sphingosine-1-phosphate stimulation of cathelicidin production | |
| BR112022019510A2 (pt) | Variantes de beta-glucocerebrosidase para uso no tratamento de doença de gaucher | |
| CO2025008932A2 (es) | Métodos para tratar la enfermedad de pompe de inicio tardío en pacientes pediátricos | |
| EA202091205A1 (ru) | Композиции для терапии гипергликемии и сопутствующих состояний | |
| Wei et al. | Mechanical ventilation induces lung and brain injury through ATP production, P2Y1 receptor activation and dopamine release | |
| WO2023150493A3 (en) | Cell therapy for diabetes | |
| AR125351A1 (es) | Composiciones y métodos para modular la expresión de pnpla3 | |
| ES2537579T3 (es) | Preparación que contiene toxina botulínica de tipo A muy purificada derivada de patógeno de botulismo del lactante | |
| BR112022014119A2 (pt) | Administração oral de peptídeos | |
| Song et al. | A glycolytic shunt via the pentose phosphate pathway is a metabolic checkpoint for nervous system sensory homeostasis and axonal regeneration | |
| BRPI0416434A (pt) | métodos para aumentar a atividade de uma proteìna de ácido esfingomielinase (asm), para estender a meia-vida e prolongar a atividade de uma proteìna asm purificada, para aumentar a produção de uma proteìna asm recombinante através de uma célula hospedeira, e usos de uma composição de asm tipo alelo-selvagem, purificada e um composto análogo de ceramida ou esfingomielina, e de um composto análogo de ceramida ou de esfingomielina | |
| Yu et al. | Exosome-Mediated Rewiring of Oxidative Stress–Inflammation–ECM Remodeling Axis Mitigates UVB-Triggered Skin Photoaging | |
| Lu et al. | Successful treatment of kerion with itraconazole and ALA-PDT: a case report | |
| BR112021019139A2 (pt) | Célula de mamífero manipulada, composição, molécula isolada de dna de fita dupla, dispositivo implantável, cápsula de hidrogel, e, método de tratamento de um paciente com doença de fabry | |
| EP4282423A4 (en) | Pharmaceutical composition for prevention or treatment of inflammatory disease or pain, comprising mesenchymal stem cells expressing ptx-3, timp1 and bdnf as active ingredient | |
| BR112022006125A2 (pt) | Composições compreendendo hialuronidase e/ou colagenase e/ou 4-metilumbeliferona (4-mu) e métodos de tratamento usando as mesmas | |
| Zhang et al. | Crotoxin potentiates L-type calcium currents and modulates the action potential of neonatal rat cardiomyocytes |